Skip to content

Self Transcranial Direct Current Stimulation for Pain in Older Adults With Knee Osteoarthritis

Self Transcranial Direct Current Stimulation for Pain in Older Adults With Knee Osteoarthritis (Self tDCS and Knee Pain)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03425019
Enrollment
21
Registered
2018-02-07
Start date
2018-03-14
Completion date
2018-10-05
Last updated
2021-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Knee Osteoarthritis

Keywords

Knee Osteoarthritis, Chronic Pain, Osteoarthritis, Transcranial Direct Current Stimulation, tDCS

Brief summary

The purpose of this study is to determine the feasibility and preliminary efficacy of two weeks of self Transcranial Direct Current Stimulation (tDCS) for pain in older patients with knee osteoarthritis (OA).

Interventions

DEVICESoterix 1x1 tDCS mini-CT Stimulator device

Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* have self-reported unilateral or bilateral knee OA pain, according to American College of Rheumatology criteria * have had knee OA pain in the past 3 months with an average of at least 3 on a 10 cm Visual Analog Scale (VAS) for pain * can speak and read English * have a device with internet access that can be used for secure video conferencing for real-time remote supervision * have access to a distraction-free, well lit, clean environment with a safe area to store the device and device kit * have no plan to change medication regimens for pain throughout the trial * are able to travel to the coordinating center * are willing and able to provide written informed consent prior to enrollment.

Exclusion criteria

* previous prosthetic knee replacement or non-arthroscopic surgery to the affected knee * history of brain surgery, tumor, seizure, stroke, or intracranial metal implantation * systemic rheumatic disorders, including rheumatoid arthritis, systemic lupus erythematosus, and fibromyalgia * uncontrolled hypertension (i.e., systolic blood pressure/ diastolic blood pressure ≥ 150/95 mm Hg) * heart failure * history of acute myocardial infarction * peripheral neuropathy * alcohol/substance abuse * cognitive impairment (i.e., Mini-Mental Status Exam score ≤ 23) * pregnancy or lactation * hospitalization within the preceding year for psychiatric illness

Design outcomes

Primary

MeasureTime frameDescription
Clinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS)baselineScores on the visual analogue scale (VAS) range from 0 (no pain) to 100 (worst pain imaginable).

Secondary

MeasureTime frameDescription
Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Stiffness SubscalebaselineThe WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.
Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Functional Impairment SubscalebaselineThe WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.
Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Summary ScalebaselineThe SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The continuous pain subscale assesses throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender, and total score on the continuous pain subscale ranges from 0-60, with a higher score indicating worse pain.
Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Subscale2 weeksThe SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The continuous pain subscale assesses throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender, and total score on the continuous pain subscale ranges from 0-60, with a higher score indicating worse pain.
Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Intermittent Pain SubscalebaselineThe SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The intermittent pain subscale assesses shooting pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, and piercing, and total score on the intermittent pain subscale ranges from 0-60, with a higher score indicating worse pain.
Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Neuropathic Pain SubscalebaselineThe SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The neuropathic pain subscale assesses hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or 'pins and needles', and numbness, and total score on the neuropathic pain subscale ranges from 0-60, with a higher score indicating worse pain.
Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Affective Description SubscalebaselineThe SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The affective description subscale assesses tiring-exhausting, sickening, fearful, and punishing-cruel, and total score on the affective description subscale ranges from 0-40, with a higher score indicating worse pain.
Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)baselineIn order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTH, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when the sensation ''first becomes painful to assess the heat pain threshold (HPTH). The temperature at which participants pressed the button to indicate the sensation ''first becomes painful is reported.
Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)baselineIn order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTO, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when they ''no longer feel able to tolerate the pain. The temperature at which participants pressed the button to indicate they could ''no longer feel able to tolerate the pain is reported.
Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)baselineIn order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's medial knee, lateral knee, or trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.
Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain SubscalebaselineThe WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.
Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM)baselineIn order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). CPM is reported as the change in PPT before and immediately following immersion of the contralateral hand up to the wrist in a cold water bath (12 degrees Celsius) for up to one minute. To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.
Number of Participants Who Were Assessed by Functional Near-infrared Spectroscopy (fNIRS)2 weeksPain-related cortical response will be measured using a continuous-wave, multichannel fNIRS imaging system (LIGHTNIRS, Shimadzu, Kyoto, Japan) with three semiconductor lasers at 780, 805, and 830 nm. Optical recordings will be collected during thermal pain stimulation.
Feasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Using Device2 weeksData will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q1) Overall the device was easy to use
Feasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Preparation of Device2 weeksData will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q2) It was easy to prepare the device and accessories
Feasibility as Assessed by a Survey of Participants' tDCS Experience - Effectiveness of Treatment Over Time2 weeksData will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q3) The effectiveness of the treatment increased over the course of treatment.
Tolerability as Assessed by Number of Participants With Side Effects2 weeksThe participants will be asked in an open-ended manner whether they have experienced any side effects, and they will then be asked specifically about tingling, itching sensation, burning sensation, pain at the stimulation site, fatigue, nervousness, headache, difficulty concentrating, mood change, and changes in vision or visual perception.
Anxiety as Assessed by the PROMIS Anxiety-short FormbaselineThe 7-item PROMIS anxiety-short form assesses the pure domain of anxiety in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety.
Depression as Assessed by the PROMIS Depression-short FormbaselineThe 8-item PROMIS depression-short form assesses the pure domain of depression in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.
Sleep Disturbance as Assessed by the PROMIS Sleep Disturbance-short FormbaselineThe 8-item PROMIS sleep disturbance-short form assesses the pure domain of sleep disturbance in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance.
Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)baselineIn order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PMP, punctate mechanical pain is delivered to the patella or hand by a calibrated nylon monofilament for 10 contacts of the monofilament at one contact per second. Participants rate the pain intensity on a scale from 0 (no pain) to 100 (maximum imaginable pain).

Countries

United States

Participant flow

Pre-assignment details

1 participant withdrew before the intervention started.

Participants by arm

ArmCount
Transcranial Direct Current Stimulation
Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
20
Total20

Baseline characteristics

CharacteristicTranscranial Direct Current Stimulation
Age, Continuous61.2 years
STANDARD_DEVIATION 7.23
Body Mass Index (BMI)28.33 kg/m^2
STANDARD_DEVIATION 8.01
Education
2-year college
5 Participants
Education
4-year college
9 Participants
Education
Doctoral degree
1 Participants
Education
High School
3 Participants
Education
Master's degree
2 Participants
Osteoarthritis duration29.60 months
STANDARD_DEVIATION 26.17
Race/Ethnicity, Customized
African American
6 Participants
Race/Ethnicity, Customized
Asian
6 Participants
Race/Ethnicity, Customized
Hispanic
1 Participants
Race/Ethnicity, Customized
White
7 Participants
Region of Enrollment
United States
20 Participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Clinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS)

Scores on the visual analogue scale (VAS) range from 0 (no pain) to 100 (worst pain imaginable).

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS)24.85 units on a scaleStandard Deviation 22.7
Primary

Clinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS)

Scores on the visual analogue scale (VAS) range from 0 (no pain) to 100 (worst pain imaginable).

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS)55.23 units on a scaleStandard Deviation 25.45
Secondary

Anxiety as Assessed by the PROMIS Anxiety-short Form

The 7-item PROMIS anxiety-short form assesses the pure domain of anxiety in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationAnxiety as Assessed by the PROMIS Anxiety-short Form13.6 score on a scaleStandard Deviation 6.73
Secondary

Anxiety as Assessed by the PROMIS Anxiety-short Form

The 7-item PROMIS anxiety-short form assesses the pure domain of anxiety in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationAnxiety as Assessed by the PROMIS Anxiety-short Form12.05 score on a scaleStandard Deviation 6.86
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Affective Description Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The affective description subscale assesses tiring-exhausting, sickening, fearful, and punishing-cruel, and total score on the affective description subscale ranges from 0-40, with a higher score indicating worse pain.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Affective Description Subscale11.7 units on a scaleStandard Deviation 11.65
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Affective Description Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The affective description subscale assesses tiring-exhausting, sickening, fearful, and punishing-cruel, and total score on the affective description subscale ranges from 0-40, with a higher score indicating worse pain.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Affective Description Subscale5.75 units on a scaleStandard Deviation 10.4
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The continuous pain subscale assesses throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender, and total score on the continuous pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Subscale14.05 units on a scaleStandard Deviation 13.84
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Summary Scale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The continuous pain subscale assesses throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender, and total score on the continuous pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Continuous Pain Summary Scale22.75 units on a scaleStandard Deviation 15.26
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Intermittent Pain Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The intermittent pain subscale assesses shooting pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, and piercing, and total score on the intermittent pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Intermittent Pain Subscale12.90 units on a scaleStandard Deviation 15.8
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Intermittent Pain Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The intermittent pain subscale assesses shooting pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, and piercing, and total score on the intermittent pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Intermittent Pain Subscale17.80 units on a scaleStandard Deviation 16.18
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Neuropathic Pain Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The neuropathic pain subscale assesses hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or 'pins and needles', and numbness, and total score on the neuropathic pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Neuropathic Pain Subscale11.1 units on a scaleStandard Deviation 13.71
Secondary

Clinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Neuropathic Pain Subscale

The SF-MPQ-2 measures the quality as well as the intensity of pain. Participants complete the SF-MPQ-2 by rating the extent to which they experienced each of 22 pain descriptors in the past week using an 11-point numeric rating scale (0 = none to 10 = worst possible). The neuropathic pain subscale assesses hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or 'pins and needles', and numbness, and total score on the neuropathic pain subscale ranges from 0-60, with a higher score indicating worse pain.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) - Neuropathic Pain Subscale8.2 units on a scaleStandard Deviation 14.23
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Functional Impairment Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Functional Impairment Subscale29.10 units on a scaleStandard Deviation 17.53
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Functional Impairment Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Functional Impairment Subscale20.85 units on a scaleStandard Deviation 15.22
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Subscale7.95 score on a scaleStandard Deviation 4.39
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Subscale5.75 units on a scaleStandard Deviation 4.25
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Stiffness Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Stiffness Subscale4.00 units on a scaleStandard Deviation 1.86
Secondary

Clinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Stiffness Subscale

The WOMAC is a self-administered questionnaire consisting of 3 subscales related to pain (pain subscale total score range, 0-20), stiffness (stiffness subscale total score range, 0-8), and impairments of physical function (functional impairment subscale range, 0-68), with higher scores indicating worse pain, stiffness, and impairments of physical function, respectively.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationClinical Pain Intensity as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Stiffness Subscale2.90 units on a scaleStandard Deviation 1.74
Secondary

Depression as Assessed by the PROMIS Depression-short Form

The 8-item PROMIS depression-short form assesses the pure domain of depression in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationDepression as Assessed by the PROMIS Depression-short Form11.85 units on a scaleStandard Deviation 6.98
Secondary

Depression as Assessed by the PROMIS Depression-short Form

The 8-item PROMIS depression-short form assesses the pure domain of depression in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationDepression as Assessed by the PROMIS Depression-short Form12.3 units on a scaleStandard Deviation 7.69
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). CPM is reported as the change in PPT before and immediately following immersion of the contralateral hand up to the wrist in a cold water bath (12 degrees Celsius) for up to one minute. To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM)0.9 kilograms force (kgf)Standard Deviation 0.7
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). CPM is reported as the change in PPT before and immediately following immersion of the contralateral hand up to the wrist in a cold water bath (12 degrees Celsius) for up to one minute. To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM)1.3 kilograms force (kgf)Standard Deviation 0.6
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTH, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when the sensation ''first becomes painful to assess the heat pain threshold (HPTH). The temperature at which participants pressed the button to indicate the sensation ''first becomes painful is reported.

Time frame: 2 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)arm37.3 degrees CelsiusStandard Deviation 2
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)knee40.1 degrees CelsiusStandard Deviation 3.4
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTH, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when the sensation ''first becomes painful to assess the heat pain threshold (HPTH). The temperature at which participants pressed the button to indicate the sensation ''first becomes painful is reported.

Time frame: baseline

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)arm37.9 degrees CelsiusStandard Deviation 3.3
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH)knee39.1 degrees CelsiusStandard Deviation 3.5
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTO, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when they ''no longer feel able to tolerate the pain. The temperature at which participants pressed the button to indicate they could ''no longer feel able to tolerate the pain is reported.

Time frame: baseline

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)arm43.2 degrees CelsiusStandard Deviation 3.1
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)knee43.1 degrees CelsiusStandard Deviation 3.3
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess HPTO, heat stimuli were delivered to the participant's arm or knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when they ''no longer feel able to tolerate the pain. The temperature at which participants pressed the button to indicate they could ''no longer feel able to tolerate the pain is reported.

Time frame: 2 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)arm43.2 degrees CelsiusStandard Deviation 3.2
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO)knee44.6 degrees CelsiusStandard Deviation 3.1
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's medial knee, lateral knee, or trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.

Time frame: 2 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)medial knee3.7 kilograms force (kgf)Standard Deviation 1.2
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)lateral knee4.4 kilograms force (kgf)Standard Deviation 1.3
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)trapezius3.9 kilograms force (kgf)Standard Deviation 1.3
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm\^2) per second to the participant's medial knee, lateral knee, or trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful. The pressure at which participants pressed the button to indicate that the pressure sensation ''first becomes painful is reported.

Time frame: baseline

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)medial knee3.2 kilograms force (kgf)Standard Deviation 1.4
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)lateral knee3.5 kilograms force (kgf)Standard Deviation 1.5
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT)trapezius2.9 kilograms force (kgf)Standard Deviation 1.6
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PMP, punctate mechanical pain is delivered to the patella or hand by a calibrated nylon monofilament for 10 contacts of the monofilament at one contact per second. Participants rate the pain intensity on a scale from 0 (no pain) to 100 (maximum imaginable pain).

Time frame: baseline

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)patella84.7 score on a scaleStandard Deviation 23.4
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)hand66.0 score on a scaleStandard Deviation 27
Secondary

Experimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)

In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH); heat pain tolerance (HPTO), pressure pain threshold (PPT), punctate mechanical pain (PMP), and Conditioned Pain Modulation (CPM). To assess PMP, punctate mechanical pain is delivered to the patella or hand by a calibrated nylon monofilament for 10 contacts of the monofilament at one contact per second. Participants rate the pain intensity on a scale from 0 (no pain) to 100 (maximum imaginable pain).

Time frame: 2 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)patella67.4 score on a scaleStandard Deviation 26.9
Transcranial Direct Current StimulationExperimental Pain Sensitivity as Assessed by a Multimodal Quantitative Sensory Testing (QST) Battery - Punctate Mechanical Pain (PMP)hand54.6 score on a scaleStandard Deviation 23.9
Secondary

Feasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Preparation of Device

Data will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q2) It was easy to prepare the device and accessories

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationFeasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Preparation of Device9.75 score on a scaleStandard Deviation 0.44
Secondary

Feasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Using Device

Data will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q1) Overall the device was easy to use

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationFeasibility as Assessed by a Survey of Participants' tDCS Experience - Ease of Using Device9.75 score on a scaleStandard Deviation 0.44
Secondary

Feasibility as Assessed by a Survey of Participants' tDCS Experience - Effectiveness of Treatment Over Time

Data will be collected on participants' tDCS experience at the conclusion of tDCS treatment on a scale of 0 (strongly disagree) to 10 (strongly agree): Q3) The effectiveness of the treatment increased over the course of treatment.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationFeasibility as Assessed by a Survey of Participants' tDCS Experience - Effectiveness of Treatment Over Time6.75 score on a scaleStandard Deviation 3.17
Secondary

Number of Participants Who Were Assessed by Functional Near-infrared Spectroscopy (fNIRS)

Pain-related cortical response will be measured using a continuous-wave, multichannel fNIRS imaging system (LIGHTNIRS, Shimadzu, Kyoto, Japan) with three semiconductor lasers at 780, 805, and 830 nm. Optical recordings will be collected during thermal pain stimulation.

Time frame: 2 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Transcranial Direct Current StimulationNumber of Participants Who Were Assessed by Functional Near-infrared Spectroscopy (fNIRS)20 Participants
Secondary

Sleep Disturbance as Assessed by the PROMIS Sleep Disturbance-short Form

The 8-item PROMIS sleep disturbance-short form assesses the pure domain of sleep disturbance in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationSleep Disturbance as Assessed by the PROMIS Sleep Disturbance-short Form24.3 units on a scaleStandard Deviation 7.87
Secondary

Sleep Disturbance as Assessed by the PROMIS Sleep Disturbance-short Form

The 8-item PROMIS sleep disturbance-short form assesses the pure domain of sleep disturbance in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance.

Time frame: 2 weeks

ArmMeasureValue (MEAN)Dispersion
Transcranial Direct Current StimulationSleep Disturbance as Assessed by the PROMIS Sleep Disturbance-short Form19.85 units on a scaleStandard Deviation 8.1
Secondary

Tolerability as Assessed by Number of Participants With Side Effects

The participants will be asked in an open-ended manner whether they have experienced any side effects, and they will then be asked specifically about tingling, itching sensation, burning sensation, pain at the stimulation site, fatigue, nervousness, headache, difficulty concentrating, mood change, and changes in vision or visual perception.

Time frame: 2 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Transcranial Direct Current StimulationTolerability as Assessed by Number of Participants With Side Effects0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026